Atara Biotherapeutics (ATRA) EBT (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported EBT for 14 consecutive years, with -$4.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 302.22% year-over-year to -$4.8 million; the trailing twelve-month figure through Jun 2026 stood at -$16.6 million (down 388.81% YoY), and the FY2025 full-year result was $32.7 million, up 138.33% from the prior year.
• EBT retreated to -$4.8 million in Q2 2026 per ATRA's latest filing, from -$4.1 million in the prior quarter.
• Across five years, EBT topped out at $38.0 million in Q1 2025 and bottomed at -$88.1 million in Q1 2022.
• Historically, EBT has averaged -$31.5 million across 5 years, with a median of -$20.5 million in 2024.
• The sharpest annual moves came in 2023 and 2025: EBT sank 485.07% in 2023, then jumped 219.8% in 2025.
• Over 5 years, EBT stood at -$74.7 million in 2022, then increased by 18.73% to -$60.7 million in 2023, then surged by 79.05% to -$12.7 million in 2024, then jumped by 73.35% to -$3.4 million in 2025, then sank by 42.65% to -$4.8 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$4.8 million, -$4.1 million, and -$3.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.